Although hepatitis C starts out as a mild disease and develops slowly, about 70% can develop slowly and eventually progress to cirrhosis without effective antiviral therapy, so antiviral therapy for hepatitis C is necessary if there are no combined contraindications. The current domestic treatment program for hepatitis C is: interferon + ribavirin, interferon and PEG interferon (Pyroxin, Pellegrin) has the best efficacy, but PEG interferon has a more pronounced effect on blood cells than ordinary interferon. If antiviral therapy is not possible, the liver should be treated with active liver protection and enzyme-lowering therapy to delay the development of cirrhosis as much as possible. Liver protection and enzyme-lowering therapy should be performed with glycopyrrolate preparations, reduced glutathione and silymarin, and it is not recommended to use bupropion and pentamidine preparations to lower glutathione transaminase, the latter enzyme-lowering therapy does not delay the development of cirrhosis.